Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890665613> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2890665613 endingPage "e23131" @default.
- W2890665613 startingPage "e23131" @default.
- W2890665613 abstract "e23131 Background: Cancer Differentiation Analysis liquid biopsy (CDA) has been investigated as a viable clinical utility in NSCLC diagnosis, as well as a new candidate for part of an overall post-CT scan clinical diagnostic and treatment decision tool kit. It has been also evaluated in NSCLC diagnosis, combined with imaging technologies. Methods: This was a retrospective investigation in which 160 individuals were recruited at Changhai Hospital of Shanghai from July to Dec. in 2014. CDA and CT scan tests were performed on all samples before final confirmation by biopsy. For CDA tests, peripheral blood was drawn in EDTA tubes before operation. A performance predication model of CDA and CT scan test results was built using pROC package in R Language for the data of Area Under the Curve (AUC) and CDA threshold values. Further analysis was carried out based on the CDA threshold values. Results: Out of the 160 individuals, 40 were diagnosed as benign lung diseases selected as control group, 120 were confirmed as NSCLC by pathology. CDA and CT test data along with epidemiological information were collected and complied. Details of other statistical results were given in the Table below. Conclusions: CDA liquid biopsy is a novel, multi-level, multi-parameter based disease diagnosis technology with improvements in multiple areas including but not limited to higher sensitivity and specificity, ability to diagnose cancer early, no side effects, and covering a wide range of cancer sites. Results showed that AUC values of CDA were higher than those of CT scan for all NSCLC stage groups. CDA plus CT scan combination has the highest average AUC value for all stages. CDA test can provide more accurate and reliable diagnostic information and data for oncologists in making crucial clinical decisions. It is expected that CDA liquid biopsy technology will play an important and critical role in NSCLC diagnosis. [Table: see text]" @default.
- W2890665613 created "2018-09-27" @default.
- W2890665613 creator A5001019377 @default.
- W2890665613 creator A5002622033 @default.
- W2890665613 creator A5022636698 @default.
- W2890665613 creator A5023740597 @default.
- W2890665613 creator A5036045846 @default.
- W2890665613 creator A5048792086 @default.
- W2890665613 creator A5052202905 @default.
- W2890665613 creator A5052279674 @default.
- W2890665613 creator A5057816982 @default.
- W2890665613 creator A5060996227 @default.
- W2890665613 date "2017-05-20" @default.
- W2890665613 modified "2023-10-16" @default.
- W2890665613 title "A novel CDA liquid biopsy technology for effective non-small cell lung cancer diagnosis." @default.
- W2890665613 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23131" @default.
- W2890665613 hasPublicationYear "2017" @default.
- W2890665613 type Work @default.
- W2890665613 sameAs 2890665613 @default.
- W2890665613 citedByCount "0" @default.
- W2890665613 crossrefType "journal-article" @default.
- W2890665613 hasAuthorship W2890665613A5001019377 @default.
- W2890665613 hasAuthorship W2890665613A5002622033 @default.
- W2890665613 hasAuthorship W2890665613A5022636698 @default.
- W2890665613 hasAuthorship W2890665613A5023740597 @default.
- W2890665613 hasAuthorship W2890665613A5036045846 @default.
- W2890665613 hasAuthorship W2890665613A5048792086 @default.
- W2890665613 hasAuthorship W2890665613A5052202905 @default.
- W2890665613 hasAuthorship W2890665613A5052279674 @default.
- W2890665613 hasAuthorship W2890665613A5057816982 @default.
- W2890665613 hasAuthorship W2890665613A5060996227 @default.
- W2890665613 hasConcept C121608353 @default.
- W2890665613 hasConcept C126322002 @default.
- W2890665613 hasConcept C126838900 @default.
- W2890665613 hasConcept C142724271 @default.
- W2890665613 hasConcept C146357865 @default.
- W2890665613 hasConcept C151730666 @default.
- W2890665613 hasConcept C2775934546 @default.
- W2890665613 hasConcept C2776256026 @default.
- W2890665613 hasConcept C2779529041 @default.
- W2890665613 hasConcept C71924100 @default.
- W2890665613 hasConcept C76318530 @default.
- W2890665613 hasConcept C86803240 @default.
- W2890665613 hasConceptScore W2890665613C121608353 @default.
- W2890665613 hasConceptScore W2890665613C126322002 @default.
- W2890665613 hasConceptScore W2890665613C126838900 @default.
- W2890665613 hasConceptScore W2890665613C142724271 @default.
- W2890665613 hasConceptScore W2890665613C146357865 @default.
- W2890665613 hasConceptScore W2890665613C151730666 @default.
- W2890665613 hasConceptScore W2890665613C2775934546 @default.
- W2890665613 hasConceptScore W2890665613C2776256026 @default.
- W2890665613 hasConceptScore W2890665613C2779529041 @default.
- W2890665613 hasConceptScore W2890665613C71924100 @default.
- W2890665613 hasConceptScore W2890665613C76318530 @default.
- W2890665613 hasConceptScore W2890665613C86803240 @default.
- W2890665613 hasIssue "15_suppl" @default.
- W2890665613 hasLocation W28906656131 @default.
- W2890665613 hasOpenAccess W2890665613 @default.
- W2890665613 hasPrimaryLocation W28906656131 @default.
- W2890665613 hasRelatedWork W2286718711 @default.
- W2890665613 hasRelatedWork W2374691485 @default.
- W2890665613 hasRelatedWork W2798455462 @default.
- W2890665613 hasRelatedWork W2976560384 @default.
- W2890665613 hasRelatedWork W2989084682 @default.
- W2890665613 hasRelatedWork W3032419867 @default.
- W2890665613 hasRelatedWork W3176360473 @default.
- W2890665613 hasRelatedWork W4244056434 @default.
- W2890665613 hasRelatedWork W4294941664 @default.
- W2890665613 hasRelatedWork W4310490811 @default.
- W2890665613 hasVolume "35" @default.
- W2890665613 isParatext "false" @default.
- W2890665613 isRetracted "false" @default.
- W2890665613 magId "2890665613" @default.
- W2890665613 workType "article" @default.